α to β cells in vivo. This occurred in response to the destruction of β cells, or after modifying the expression of critical transcription factors, respectively. However, a means of achieving such a fate switch in a controlled and therapeutically tractable manner has so far proved elusive.
Firstly, Li et al. [5] established an assay for Arx function, a transcription factor required to maintain α cell phenotype. Overexpression of this factor in the clonal β cell line MIN6 provided the basis of a screen for small molecules which inhibited Arx, consequently increasing insulin gene expression. In this way, the authors identified artemisinins, including the antimalarial drug artemether, as effective regulators of Arx function and cell identity. A further chemical proteomics screen then identified gephyrin as the likely receptor for artemether. Gephyrin is a key regulator of γ-aminobutyric acid (GABA) synthesis and GABA A receptor trafficking. Strikingly, artemether increased β cell numbers in vivo in both mice and zebrafish, and lineage tracing analysis showed that this was due to α to β cell conversion [5] . Artemether-treated clonal α cells (αTC1-6) also displayed Arx exclusion from the nucleus and altered depolarization-induced Ca 2+ dynamics [5] , consistent with enhanced GABA A receptor expression. Importantly, single cell RNA-seq experiments demonstrated similar effects in human α cells.
Complementing the above study, Ben-Othman and co-workers [6] performed a transcriptional screen to identify genes upregulated by overexpression of Pax4 in α cells, a manoeuvre which favors α to β cell switching [6] .
Many of the most strongly upregulated genes were involved in GABA signaling. Correspondingly, treatment of αTC1-6 cells with GABA decreased the expression of Arx, suggesting that the neurotransmitter favors the conversion of α to β cells in vivo. Providing a direct demonstration of this hypothesis, treatment of mice for 2-6 months led to a remarkable (> 3-fold) increase in β cell mass. Again, lineage tracing using a glucagon promoter-driven Cre to drive β-gal expression revealed that the vast majority of the "additional" β cells were derived from a glucagon-positive progenitor.
Extending this work to a model of T1 DM, these authors [6] went on to show that the effects of β cell destruction with the chemical agent streptozotocin were reversed by GABA and that this resulted from the generation of β from α cells.
There are, nonetheless, several intriguing aspects of these studies which will require further investigations. Firstly, within the intact healthy islet, GABA is chiefly released from β cells and, at least in the case of rodent islets where blood flow is known to be in the direction of β to α cells [7] , is likely then to act on α cells. According to the new findings, GABA action should consequently favor conversion of α to β cells. The loss of this input therefore seems unlikely to explain α to β cell conversion after the artificial destruction of β cells in mice [3] and would be expected to hinder β cell neogenesis after this destruction of these cells in T1 DM.
Secondly, what signaling mechanisms within α cells are responsible for the observed changes in Arx expression, and ultimately the switch to a β cell phe-notype? Whilst increased Ca 2+ can elicit dramatic changes in cellular phenotype, for example after oocyte fertilization [8] , how a decrease in Ca What is the immediate translational potential of these results? GABA A receptor agonists are in current clinical use as a treatment for epilepsy [9] whilst artemether is widely deployed as an antimalarial drug [10] . Both are therefore considered safe for use in humans. Clinical trials with these agents should therefore be feasible and should reveal whether GABA treatment might provide the basis of exciting new regenerative treatments for T1 DM (Figure 1 ). 
